A study of a GLP-1 and GIP medicine, tirzepatide, in people with mild autonomous cortisol secretion (MACS).

Recruiting now. Registry record last updated July 30, 2026.

Who can join: Adults 18+, have mild autonomous cortisol secretion (MACS), BMI 27+.
What you take: Tirzepatide, given as part of the study. Check ClinicalTrials.gov for this trial's study groups, including any placebo or comparison medicine.
How long it lasts: The full study runs about 2 years.
What you get: Costs vary by study. Ask the study team what this one covers, including the study medicine, visits and travel, before you sign the consent form.

This one may not fit you. We check your age, where you live, and the rules each study sets, then show the clinical trials that do.

Check my fit →

Phase Phase 2Sponsor Alaa SadaDrug tirzepatideClass GLP-1/GIPSites 1 USEnrollment target 34

What this study is for

Primary condition: Mild Autonomous Cortisol Secretion (MACS). Also studied in: Adrenalectomy; Status.

Full scientific study title: Tirzepatide Following Adrenalectomy in Mild Autonomous Cortisol Secretion.

Who can join

Age18 and upSexAnyBMI27 or higher

Adults 18+, have mild autonomous cortisol secretion (MACS), BMI 27+. A site coordinator confirms whether you qualify during a free screening visit. The exact medical requirements are below.

Full medical eligibility (for you and your doctor)verbatim from the registry

This is the exact wording from ClinicalTrials.gov, including clinical measures (lab values, imaging scores). Bring it to your doctor if any of it is unclear.

Key inclusion criteria

Adults aged 18 years and older
Diagnosis of MACS, defined as morning cortisol \>1.8 mcg/dL after a 1 mg dexamethasone suppression test
Elevated blood pressure (SBP ≥120 mmHg or DBP ≥80 mmHg per the 2025 American College of Cardiology/American Heart Association \[ACC/AHA\] criteria, or current use of antihypertensive medication)
BMI ≥27
Undergoing or having undergone adrenalectomy for the treatment of MACS

Key exclusion criteria

Bilateral adrenal lesions
Adrenal malignancy
Concurrent primary aldosteronism with MACS
Current use of GLP-1 receptor agonists
Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)

Where this trial is enrolling

This trial has 1 sites across 1 state. Contact a site coordinator directly to start screening.

Pennsylvania1 site

University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania

Follow this trial

We email you if NCT07573163 changes status, adds new sites in your state, or if a similar trial opens for the same condition.

Timeline

Started enrolling: July 27, 2026. Expected completion: December 31, 2028. Last updated on ClinicalTrials.gov: July 30, 2026.

Official source

Every Monday we check this trial against ClinicalTrials.gov, the federal registry for clinical research. Last checked September 4, 2026. Confirm the current status there before you contact a site:

View on ClinicalTrials.gov →

Back to the full directory → or take the matching quiz if you want clinical trials filtered to your conditions and location.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site LinkedIn Contact

Why you can trust GLP Chart. Same scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.